Pierpaolo Turcano1, Michelle M Mielke1, James H Bower1, Joseph E Parisi1, Jeremy K Cutsforth-Gregory1, J Eric Ahlskog1, Rodolfo Savica2. 1. From the Departments of Neurology (P.T., M.M.M., J.H.B., J.K.C.-G., J.E.A., R.S.), Health Science Research (M.M.M.), and Laboratory Medicine and Pathology (J.E.P.), Mayo Clinic, Rochester, MN. 2. From the Departments of Neurology (P.T., M.M.M., J.H.B., J.K.C.-G., J.E.A., R.S.), Health Science Research (M.M.M.), and Laboratory Medicine and Pathology (J.E.P.), Mayo Clinic, Rochester, MN. Savica.Rodolfo@mayo.edu.
Abstract
OBJECTIVE: To assess dyskinesia frequency in a population-based cohort of patients with Parkinson disease (PD). Dyskinesia complicates levodopa treatment and affects quality of life. METHODS: Utilizing the 1991-2010 population-based, parkinsonism-incident cohort of Olmsted County, MN (n = 669), accessed via the Rochester Epidemiology Project, we identified patients with PD and abstracted levodopa-related dyskinesia information. RESULTS: Of 309 patients with PD (46.2% with parkinsonisms), 279 (90.3%) received levodopa. Most (230/279; 82.4%) had been treated by a Mayo Clinic neurologist. Median age of the 309 patients with PD at the time of diagnosis was 74.1 years (range 33.1-97.8 years). Median-age levodopa initiation in this cohort was 75 years (range 37-98 years), and median-duration levodopa treatment was 6 years (range 2 months to 19.8 years). Dyskinesia was documented in 84 of 279 patients (30.1%). Median time from levodopa initiation to dyskinesia onset was 4 years (range 2 months to 20 years); those with dyskinesia (65.5%; 55/84) developed it within 5 years of levodopa initiation (9 within the first year). Dyskinesia was mild in 57/84 (67.9%), moderate in 16/84 (19.1%), and severe in 9/84 (10.7%); severity was not reported in 2 cases. Dyskinesia severity led to levodopa adjustments or amantadine initiation in 60.7% (51/84 of those with dyskinesia), with improvement in 23/51 (45.1%). Thirteen patients with dyskinesia underwent deep brain stimulation, reporting marked improvement. Postmortem examination confirmed Lewy body disease in 7 autopsied cases. CONCLUSIONS: Levodopa-induced dyskinesia affected 30% of the patients with PD in our cohort. Mayo neurologists favoring levodopa dosage optimization treated most patients. Dyskinesia was severe in 3.2% of all levodopa-treated patients with PD (10.7% of all patients with dyskinesia) with marked improvement among those treated with deep brain stimulation.
OBJECTIVE: To assess dyskinesia frequency in a population-based cohort of patients with Parkinson disease (PD). Dyskinesia complicates levodopa treatment and affects quality of life. METHODS: Utilizing the 1991-2010 population-based, parkinsonism-incident cohort of Olmsted County, MN (n = 669), accessed via the Rochester Epidemiology Project, we identified patients with PD and abstracted levodopa-related dyskinesia information. RESULTS: Of 309 patients with PD (46.2% with parkinsonisms), 279 (90.3%) received levodopa. Most (230/279; 82.4%) had been treated by a Mayo Clinic neurologist. Median age of the 309 patients with PD at the time of diagnosis was 74.1 years (range 33.1-97.8 years). Median-age levodopa initiation in this cohort was 75 years (range 37-98 years), and median-duration levodopa treatment was 6 years (range 2 months to 19.8 years). Dyskinesia was documented in 84 of 279 patients (30.1%). Median time from levodopa initiation to dyskinesia onset was 4 years (range 2 months to 20 years); those with dyskinesia (65.5%; 55/84) developed it within 5 years of levodopa initiation (9 within the first year). Dyskinesia was mild in 57/84 (67.9%), moderate in 16/84 (19.1%), and severe in 9/84 (10.7%); severity was not reported in 2 cases. Dyskinesia severity led to levodopa adjustments or amantadine initiation in 60.7% (51/84 of those with dyskinesia), with improvement in 23/51 (45.1%). Thirteen patients with dyskinesia underwent deep brain stimulation, reporting marked improvement. Postmortem examination confirmed Lewy body disease in 7 autopsied cases. CONCLUSIONS:Levodopa-induced dyskinesia affected 30% of the patients with PD in our cohort. Mayo neurologists favoring levodopa dosage optimization treated most patients. Dyskinesia was severe in 3.2% of all levodopa-treated patients with PD (10.7% of all patients with dyskinesia) with marked improvement among those treated with deep brain stimulation.
Authors: A Hassan; J H Bower; N Kumar; J Y Matsumoto; R D Fealey; K A Josephs; J E Ahlskog Journal: Parkinsonism Relat Disord Date: 2011-02-09 Impact factor: 4.891
Authors: Erinaldo Ubirajara Damasceno Dos Santos; Isaura Isabelle Fonseca Gomes da Silva; Amdore Guescel C Asano; Nadja Maria Jorge Asano; Maria De Mascena Diniz Maia; Paulo Roberto Eleutério de Souza Journal: Mol Biol Rep Date: 2020-11-05 Impact factor: 2.316
Authors: Pierpaolo Turcano; Cole D Stang; James H Bower; J Eric Ahlskog; Bradley F Boeve; Michelle M Mielke; Rodolfo Savica Journal: Neurol Clin Pract Date: 2020-04
Authors: Emanuele Camerucci; Cole D Stang; Mania Hajeb; Pierpaolo Turcano; Aidan F Mullan; Peter Martin; Owen A Ross; James H Bower; Michelle M Mielke; Rodolfo Savica Journal: J Parkinsons Dis Date: 2021 Impact factor: 5.520
Authors: Han-Joon Kim; Sarah Mason; Thomas Foltynie; Sophie Winder-Rhodes; Roger A Barker; Caroline H Williams-Gray Journal: Mov Disord Date: 2019-11-11 Impact factor: 10.338
Authors: Bart Post; Lieneke van den Heuvel; Teije van Prooije; Xander van Ruissen; Bart van de Warrenburg; Jorik Nonnekes Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568